Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03874689
Other study ID # TEPIM
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2019
Est. completion date December 31, 2022

Study information

Verified date November 2023
Source Technical University of Munich
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to determine the prevalence of taeniosis and (neuro)cysticercosis in two districts in the southern (Gwembe) and eastern province (Chipata) of Zambia.


Description:

The true prevalence of Neurocyticercosis in Zambia is not well known. Only one study which was a pilot study done in Katete district of eastern province demonstrated the prevalence of NCC among people with epilepsy. There is need to provide an accurate estimate of the prevalence of NCC among people with cysticercosis in Zambia as well as understand the clinical manifestations of the disease in humans. Data on the full range of clinical characteristics of NCC is essential to accurately estimate the burden of the disease in the community. The epidemiology work package within the human health sector will create awareness of the size of the problem by delivering scientifically generated prevalence data on TSCT and NCC in various population groups (adults, children, and those living with epilepsy) in two provinces of Zambia. This will form an essential prerequisite for the development of public health policy guidelines for the control/elimination of TSCT/NCC in the country. Further, environmental factors that could play a role in the transmission and maintenance of T. solium eggs will be studied. This will provide essential data in understanding the epidemiology of the parasite in endemic regions.


Recruitment information / eligibility

Status Completed
Enrollment 2921
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 10 Years and older
Eligibility Inclusion Criteria: - Willing and able to participate in all aspects of the study, including providing blood and stool samples, participating in a questionnaire survey and group discussions, and taking oral anthelmintic tablets - Willing and able to provide informed consent (signature or thumbprint with impartial witness; assent for minors with parental consent). - Living in, attending school in, or regularly visiting the bore holes present in, the study communities. - Aged 10 years or older Exclusion Criteria: - Unwilling or unable to participate in some or all aspects of the study, including providing blood and stool samples, participating in a questionnaire survey and group discussions, or taking oral anthelmintic tablets. - Unwilling or unable to provide written (signature or thumbprint with impartial witness) informed consent (or assent for minors). - Living outside of, and not regularly visiting, or attending school in, the study communities. - Children aged less than 10 years. - Seriously ill individuals (people unable to engage in the normal activities of daily living without assistance because of their illnesses).

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Zambia University of Zambia Lusaka

Sponsors (1)

Lead Sponsor Collaborator
Technical University of Munich

Country where clinical trial is conducted

Zambia, 

References & Publications (1)

Zulu G, Sikasunge CS, Welte TM, Simuunza MC, Stelzle D, Schmidt V, Hachangu A, Mutale W, Masuku M, Chembensofu M, da Costa CP, Mwape KE, Winkler AS, Phiri IK. Epidemiology of intestinal helminthiasis with an emphasis on taeniasis in Chipata district of th — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of T. solium cysticercosis Prevalence of human T. solium cysticercosis Assessment through blood sampling at baseline
Primary Prevalence of neurocysticercosis Prevalence of human neurocysticercosis among people with positive serology for T. solium cysticercosis Assessment at CT scanning at baseline
Primary Prevalence of taeniosis Prevalence of human T. solium taeniosis Assessment through stool sampling at baseline
Secondary Prevalence of intestinal helminth infection Prevalence of intestinal helminth infection Assessment through stool sampling at baseline
See also
  Status Clinical Trial Phase
Completed NCT00526916 - PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28 Phase 1
Completed NCT00527579 - PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB Phase 1
Terminated NCT02233855 - People Presenting With Neurocysticercosis in North America
Completed NCT02234570 - Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole Phase 1
Terminated NCT02947581 - Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO) Phase 3
Completed NCT02243644 - Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT Phase 3
Not yet recruiting NCT06376396 - Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis Phase 4
Completed NCT00441285 - Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ) Phase 2/Phase 3
Not yet recruiting NCT04706819 - Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study
Completed NCT00283699 - A Pilot Study of Neurocysticercosis Treatment Phase 3
Terminated NCT02945527 - Treatment of Peri-calcification Edema in Neurocysticercosis (NCC) Phase 2/Phase 3
Completed NCT00290823 - Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients Phase 3
Completed NCT03834337 - Treatment of Patients With Active Neurocysticercosis in Eastern Africa
Completed NCT03851419 - The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania